Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of 177Lu-rhPSMA-10.1 in PSMA-positive metastatic castration-resistant prostate cancer
2022-002407-37Phase 2Active
- Sponsor
- Blue Earth Therapeutics
- Start
- Dec 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium (177Lu) rhPSMA-10.1 in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Blue Earth Therapeutics. Primary endpoint: PSA response during treatment period. Started Dec 2022; status: active.
02
Drugs
lutetium (177Lu) rhPSMA-10.1
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2022-002407-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002407-37.